Evofem Biosciences, Inc. (EVFM)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Evofem Biosciences, Inc. reported revenue of $20.18M, up 4.2% from the prior year. The company was profitable, with a net margin of 1.9%. It held $20.27M in total assets against $89.71M in total liabilities.
Key ratios (FY2025)
16.7%
Operating margin
1.9%
Net margin
+4.2%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $20.18M | $19.36M | $18.22M | $16.84M | — | — | — | — | — | — |
| Cost of Revenue | $4.62M | $3.83M | $6.51M | $4.42M | $4.05M | $468.0K | $0 | — | — | — |
| Operating Income | $3.37M | -$7.68M | -$17.85M | -$84.12M | -$166.80M | -$103.62M | -$52.74M | -$77.64M | -$35.69M | -$12.04M |
| Net Income | $391.0K | -$8.86M | $52.98M | -$76.70M | -$205.19M | -$142.31M | -$80.03M | -$125.71M | -$105.31M | -$13.02M |
| EPS (Diluted) | $0.00 | $-0.11 | $0.05 | $-167.42 | $-23.63 | $-2.12 | — | — | — | — |
| Total Assets | $20.27M | $23.79M | $10.55M | $25.16M | $42.51M | $109.97M | $28.30M | $4.01M | $3.95M | $12.82M |
| Total Liabilities | $89.71M | $90.26M | $72.47M | $96.96M | $142.09M | $108.62M | $12.66M | $27.37M | $103.63M | — |
| Shareholders' Equity | -$74.34M | -$71.26M | -$66.51M | -$71.80M | -$104.31M | $1.35M | $15.64M | -$23.36M | -$289.55M | -$181.09M |
| Cash & Equivalents | $578.0K | $741.0K | — | $2.77M | $7.73M | $48.89M | $15.57M | $1.33M | $1.21M | $11.48M |
| Operating Cash Flow | -$1.99M | -$3.88M | -$8.97M | -$70.41M | -$146.67M | -$104.83M | -$55.10M | -$56.50M | — | — |
| Capital Expenditures | $5.0K | $14.0K | $4.0K | $341.0K | $2.94M | $2.25M | $164.0K | $7.0K | $6.0K | — |
| Shares Outstanding | 126.69M | 113.36M | 20.01M | 984.8K | 10.83M | 81.35M | 48.14M | 25.87M | 2.08M | 2.30M |